Therapeutic options for hormone-refractory prostate cancer in 2007

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 5, 2007, Pages 413-419

  Hadaschik, Boris A ^a   Gleave, Martin E ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antisense oligonucleotides; Hormone refractory; Prostate cancer; Small molecule inhibitors; Targeted therapy

Indexed keywords

AEG 35156; ANDROGEN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; APRINOCARSEN; ASENTAR; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CARBOPLATIN; CGP 69846A; CYTOTOXIC AGENT; DN 101; DOCETAXEL; ESTRAMUSTINE; GENE EXPRESSION MODULATOR 231; GTI 2040; GTI 2501; IMATINIB; ISIS 23722; ISIS 3521; IXABEPILONE; LY 2181308; LY 2275796; MITOXANTRONE; OBLIMERSEN; OGX 011; OGX 225; OGX 427; OGYX 427; PACLITAXEL; PREDNISONE; SATRAPLATIN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CLONE; GENE TARGETING; HEADACHE; HUMAN; LEUKEMIA; LUNG CANCER; MALE; MELANOMA; METASTASIS; MYELOMA; PERIPHERAL EDEMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; THROMBOSIS; TREATMENT RESPONSE; UNITED STATES;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CHOLECALCIFEROL; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MITOXANTRONE; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; ORGANOPLATINUM COMPOUNDS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 34548438462     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.05.010     Document Type: Review

References (70)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Oh W.K., and Kantoff P.W. Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 160 (1998) 1220-1229
3. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
4. So A., Gleave M., Hurtado-Col A., et al. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23 (2005) 1-9
5. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1109
6. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
7. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
8. Fleming M.T., Morris M.J., Heller G., et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 3 (2006) 658-667
9. Gasparini G., Longo R., Toi M., et al. Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat Clin Pract Oncol 2 (2005) 562-577
10. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 (2003) 401-410
11. Weidner N., Carroll P.R., Flax J., et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
12. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3 (2005) 11-16
13. Shariat S.F., Anwuri V.A., Lamb D.J., et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22 (2004) 1655-1663
14. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
15. Picus J., Halabi S., Rini B., et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Proc Am Soc Clin Oncol 22 (2003) 1578 [Abstract]
16. Oh W.K., Halabi S., Kelly W.K., et al. A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 98 (2003) 2592-2598
17. Ryan C.J., Lin A.M., and Small E.J. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urol Oncol 24 (2006) 250-253
18. Ning Y.M., Arlen P.M., Gulley J., et al. A Phase II trial of docetaxel, thalidomide, bevacizumab, and prednisone in patients with metastatic androgen-independent prostate cancer (AIPC). ASCO 24 (2006) 13037 [Abstract]
19. Teo S.K. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 7 (2005) E14-E19
20. Figg W.D., Dahut W., Duray P., et al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7 (2001) 1888-1893
21. Dahut W.L., Gulley J.L., Arlen P.M., et al. Randomized Phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
22. Mathew P., Logothetis C.J., Dieringer P.Y., et al. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5 (2006) 144-149
23. Nelson J., Bagnato A., Battistini B., et al. The endothelin axis: Emerging role in cancer. Nat Rev Cancer 3 (2003) 110-116
24. Carducci M.A., and Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12 (2006) 6296s-6300s
25. Carducci M.A., Padley R.J., Breul J., et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, Phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679-689
26. Carducci M., Nelson J.B., Saad F., et al. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. J Clin Oncol 22 (2004) 4508 [Abstract]
27. Vogelzang N.J., Nelson J.B., Schulman C.C., et al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 4563 [Abstract]
28. Mathew P., Fidler I.J., and Logothetis C.J. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol 31 (2004) 24-29
29. Kim S.J., Uehara H., Yazici S., et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98 (2006) 783-793
30. Lin A.M., Rini B.I., Weinberg V., et al. A Phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98 (2006) 763-769
31. Oh W.K., Tay M.H., and Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?. Cancer 109 (2007) 477-486
32. Choy H. Satraplatin: An orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther 6 (2006) 973-982
33. Sternberg C.N., Whelan P., Hetherington J., et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68 (2005) 2-9
34. Nathan F.E., Sternberg C., Sartor O., et al. Satraplatin: A new treatment option for patients with hormone refractory prostate cancer. ASCO 23 (2005) 4802 [Abstract]
35. Bhandari M.S., and Hussain M. Epothilones and the next generation of Phase III trials for prostate cancer. BJU Int 96 (2005) 296-302
36. Hussain M., Tangen C.M., Lara Jr. P.N., et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: A southwest oncology group trial S0111. J Clin Oncol 23 (2005) 8724-8729
37. Galsky M.D., Small E.J., Oh W.K., et al. Multi-institutional randomized Phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23 (2005) 1439-1446
38. Goodin S., Kane M.P., and Rubin E.H. Epothilones: Mechanism of action and biologic activity. J Clin Oncol 22 (2004) 2015-2025
39. Lin A.M., Rosenberg J.E., Weinberg V.K., et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol 24 (2006) 4558 [Abstract]
40. Beer T.M., and Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res 26 (2006) 2647-2651
41. Beer T.M., Ryan C.W., Venner P.M., et al. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J Clin Oncol 23 (2005) 4516 [Abstract]
42. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
43. Rai K.R., Moore J.O., Boyd T.E., et al. Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense; genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). ASH 104 (2004) 338 [Abstract]
44. Chanan-Khan A.A., Niesvizky R., Hohl R.J., et al. Randomized multicenter Phase III trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139; Bcl-2 antisense; genasense) for patients with advanced multiple myeloma (MM). ASH 104 (2004) 1477 [Abstract]
45. Lynch T.J., Raju R., Lind M., et al. Randomized Phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. Proc Am Soc Clin Oncol 22 (2003) 2504 [Abstract]
46. Paz-Ares L., Douillard J.Y., Koralewski P., et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-α antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24 (2006) 1428-1434
47. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group. J Clin Oncol 24 (2006) 4738-4745
48. Shannan B., Seifert M., Leskov K., et al. Challenge and promise: Roles for clusterin in pathogenesis, progression, and therapy of cancer. Cell Death Differ 13 (2006) 12-19
49. Wilson M.R., and Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 25 (2000) 95-98
50. Steinberg J., Oyasu R., Lang S., et al. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 3 (1997) 1707-1711
51. Yamanaka K., Gleave M.E., Hara I., et al. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 4 (2005) 187-195
52. Miyake H., Muramaki M., Kurahashi T., et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 68 (2006) 609-614
53. July L.V., Akbari M., Zellweger T., et al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50 (2002) 179-188
54. Miyake H., Nelson C., Rennie P.S., et al. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60 (2000) 170-176
55. Miyake H., Chi K.N., and Gleave M.E. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6 (2000) 1655-1663
56. Zellweger T., Chi K., Miyake H., et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8 (2002) 3276-3284
57. Trougakos I.P., So A., Jansen B., et al. Silencing expression of the clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res 64 (2004) 1834-1842
58. Zellweger T., Miyake H., Cooper S., et al. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298 (2001) 934-940
59. Chi K.N., Eisenhauer E., Fazli L., et al. A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2>29>-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (2005) 1287-1296
60. Chi K.N., Eisenhauer E., Siu L., et al. A Phase I study of a second-generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND. 154. J Clin Oncol 23 (2005) 3085 [Abstract]
61. Fan H., Villegas C., Huang A., et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58 (1998) 1650-1653
62. Lee Y., Vassilakos A., Feng N., et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 63 (2003) 2802-2811
63. Desai A.A., Schilsky R.L., Young A., et al. A Phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16 (2005) 958-965
64. Sridhar S.S., Canil C.M., Hotte S.J., et al. A Phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). J Clin Oncol 24 (2006) 13015 [Abstract]
65. Bubendorf L., Kolmer M., Kononen J., et al. Hormone therapy failure in human prostate cancer: Analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 91 (1999) 1758-1764
66. Cornford P.A., Dodson A.R., Parsons K.F., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60 (2000) 7099-7105
67. Rocchi P., So A., Kojima S., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64 (2004) 6595-6602
68. Miyake H., Muramaki M., Kurahashi T., et al. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anticancer Res 26 (2006) 1583-1587
69. Concannon C.G., Gorman A.M., and Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 8 (2003) 61-70
70. Ciocca D.R., and Calderwood S.K. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10 (2005) 86-103